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ABBREVIATIONS
ADP: adenosyne diphosphate 
AMP: adenosyne monophosphate 
ATP: adenosyne triphosphate 
adenocc.: adenocarcinoma
ATBC study: Alpha-Tocopherol, B-Carotene Cancer Prevention study
BMI: body mass index
cAMP: cyclic adenosyne monophosphate
CARET: B-Carotene and Retinol Efficacy Trial
cc.: carcinoma
CD: Crohn’s disease
CDAI: Crohn’s disease activity index
FAP: familiar adenomatous polyposis
GI: gastrointestinal
IBD: inflammatory bowel disease
IND: indomethacin
NSAIDs: non-steroidal antiinflammatory drugs
PCs: prostaglandins
PHS: Physician’s Health Study
UC: ulcerative colitis
1. INTRODUCTION
1.1 Biochemistry of retinoids and carotenoids
Retinoids are a class of compounds consisting of four isoprenoid units bound in a head-to-tail
five carbon-carbon double bounds and a functional group at the terminus of the acyclic portion 
(44) Vitamin A is a fat-soluble substance found in animal foods and dairy products. Vitamin A is 
available as preformed vitamin A, contained in liver, cod liver oil, butter, eggs, or as pro-vitamin 
A carotenoids, as found in dark green, red and yellow vegetables (7). These naturally occuring 
retinoids exist in the all-trans, 13-cis or 11-cis geometric configurations, with the great 
preponderance of the body’s retinoids being present in the all-trans configuration (8). The 
alcohol all-trans retinol is the parent compound for all retinoids. Retinol is the precursor for 
synthesis of the biologically active retinadehyde and retinoic acid forms. Additionally, retinol is 
the precursor for the synthesis of retinyl esters (8). Within target tissues retinol is taken up by 
the cells from circulation and can either be oxidized to retinaldehyde, retinoic acid or esterified 
for storage (33). Retinaldehyde is not known to play another essential physiological role outside 
the vision, aside from serving as an intermediate in the enzimatic oxidation of retinol to retinoic 
acid (109). Retinoic acid is the biologically active retinoid form which is needed for mediating 
and maintaining cellular differentation (104).
1.2. Physiology of retinoids and carotenoids
All retinoids in the body originate in the diet either as provitamin A carotenoids or as 
preformed vitamin A (33). The dietary carotenoids and preformed retinoids undergo a series of 
metabolic conversions, extracellularly in the lumen of the intestine and intracellularly in the 
intestinal mucosa, which result in the preponderance of the absorbed dietary' retinoid being 
converted to retinol (114). Pro-vitamin A carotenoids, such as B-carotene, may be converted to
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retinaldehyde through the cleavage by carotenoid-15.1 S’-dioxvgenase or by an excentric 
cleavage pathway. Approximately 50 of over 600 carotenoids found in nature may be converted 
to vitamin A (114). The bioavailability of pro-vitamin A carotenoids is much less that of 
preformed vitamin A because of a variety of factors, including differences in efficacy of 
absorption and biochemical conversion (114). Although hundreds of carotenoids have been 
identified, only few have been found to exist in appreciable concentrations in human serum: 
lutein, zeaxanthin, a- and P-carotene, a- and P-cryptoxanthin (6).
Retinol is esterified in the intestinal mucosa, packaged as retinyl ester into chylomicra, and 
carried to the liver via the lymphatic circulation (8). A very small portion of the dietary retinoid 
is converted to retinoic acid (or comes in the diet as such) and enters the circulation through the 
portal system bouna to serum aioumin {i  i oj .
Approximately 90% of vitamin A in the body is stored in the liver as retinyl esters 
(37,43,138). The liver has the capacity to store enough vitamin A to last for several months, 
with longer storage capacity among adults than children (133). Retinol is released from the liver 
in combination with plasma retinol-binding protein (RBP) and transthyretin (TTR) (93,117). 
Retinol is poorly soluble in water and is carried in the blood sequestered inside the carrier 
proteins (124). Retinol seems to enter cells via specific receptors, although it is unclear whether 
all cells contain these receptors (117).
Vitamin A exerts its effects through retinoid receptors, which are found in the nucleus of 
cells. These receptors resemble steroid and thyreoid hormone receptors and support the idea 
that vitamin A acts much like a hormone (104). Retinol is converted into its active metabolite, 
all-trans-retinoic acid (ATRA) in the cells Retinoic acid can control genes through specific 
receptors that belong to the superfamily of thyroid and steroid receptors (17,18). Retinoid acid 
receptors act as transcriptional activators for specific target genes. The retinoic acid receptor 
(RAR) is expressed as several isoforms referred to as RAR a-, (3- and y for which all-trans­
retinoic acid acts as a ligand), and retinoid X receptors (RXR) referred to as RXR a-. B- and y 
for which 9-cis retinoic acid acts as a ligand (54). 9-cis retinoic acid seems to be functionally 
distinct from ATRA, and interconversion is may exist between the two isomers. Each RAR and 
RXR has a specific DNA-binding domain, a retinoic acid response element (RARE) by which 
these nuclear receptors may affect retinoic acid tranciptional activity. RAR and RXR receptors 
form heterodimers which bind to DNA and control gene activity. In addition, RXR receptors 
also can form heterodimers with vitamin D and thyroid hormone receptors (54). Numerous 
studies focus recently on the role of retinoid receptors in the process of carcinogenesis 
(4,57,63,1 15,132,139).
Retinoids and carotenoids have numerous biological functions (see detailed in discussion) such 
as reguiating oi growui, morpnogenesis anu uiiieienuaiion oi ecus, mey nave a vanciy u. cuccls 
on the cell membrane, they can influence the activity of different enzymes furthermore these 
compounds exert also immunomodulatory effects. Carotenoids are non-enzymatic antioxidants, 
therefore they are able to prevent genetic changes by preventing DNA damage caused by free 
radicals. They modulate membrane functions and stabilise initiated cells in promotional phase of 
carcinogenesis (114).
The role of retinoids in GI mucosal prevention has been intensively investigated in our 
department in the last two decades. Vitamin A and beta-carotene were shown to prevent the 
experimentally induced gastric mucosal lesions in animals (48), and these compounds were 
found to be effective in the treatment of patients with gastric peptic ulcer (97). Carotenoids 
have no inhibitory effects on gastric acid secretion neither in animals (48) nor in humans (42), 
however P-carotene was able to prevent the gastric mucosal damage in different experimental 
models such as ethanol (96 %) hydrochloric acid (0,6 M) - or indomethacin-induced mucosal 
damage (42,48,97) Furthermore the ulcer healing effect of vitamin A was proven in 
randomized, multicenter clinical studies (97). The gastroprotection induced by carotenoids does
not depend on the presence of vitamin A activity, [3-ionone ring, number of unsaturated links or 
chemical structure of terminal part of molecules (48,74). Moreover, the analysis of gastric 
mucosal antioxidant mechanisms and free radical generation during P-carotene-induced gastric 
mucosa! protection suggested that the scavenger character of R-carotene might nartiallv explain 
its protective effect (129). The P-carotene-induced gastric gastroprotection was completely 
abolished by acute bilateral surgical vagotomy (130). Despite of these investigations, the exact 
mechanism of action is not fully understood yet.
Although carotenoids, such as B-carotene, and vitamin A are often popularly regarded to be 
equivalent, there are large differences in biological functions of these two nutrients, especially 
regarding to antioxidant properties, since vitamin A is a less potent antioxidant that B-carotene 
(114).
1.3. Retinoids and chemical carcinogenesis
A suboptimal diet might be related to approximately 30-60% of all cancer cases (98) the major part 
of which is possibly preventable by adequate dietary modifications (26). Chemopreventive potentials 
are conceivable for antioxidant micronutritients (9,11,12). Particularly intriguing are those with 
polyene structure, i.e. vitamin A-type retinoids and carotenoids such as B-carotene (5,136,140).
Several animal and in vitro studies have now been reported related to the effects of 
antioxidants on cell proliferation, including GI epithelial cell proliferation. It has been observed 
70 years before that the deficiency of vitamin A in animals provokes abnormal keratinizations, 
precancerous squamous metaplasia and cancers of various epithelia (137). The effectiveness of 
retinoids as inhibitors of chemical carcinogenesis of the epithelia of the digestive tract has been 
somewhat contradictious, although positive results have been obtained in studies of stomach, 
esophageal, liver and pancreatic carcinogenesis. The oral administration of retinyl ester prevented the 
occurence of papillomas and carcinomas in hamsters receiving polycyclic hydrocarbons (73).
Nitrosamine-induced esophageal carcinogenesis can also markedly be inhibited by administering 
retinyl-ester (72). Subsequent studies have shown that that synthetic retinoids such as 13-cis-retinoic 
acid also exert a protective effect against the induction of esophageal tumors with nitroso 
compounds, although etretinate was ineffective in in inhibiting esophageal carcinogenesis (73). Only 
few and contradictious data can be found concerning the effect of retinoids on chemically induced 
colon carcinogenesis. An antioxidant mixture containing B-carotene and a-tocopherol reduced 
cell proliferation in the colon and rectum of mice (58). Organic and inorganic selenium with B- 
carotene reduced colonic epithelial cell proliferation while concomitantly reducing the incidence 
and multiplicity of colon adenocarcinomas in rats given chemical carcinogens (92). Colorectal 
epithelial cell proliferation was reduced in rats given chemical carcinogens when given a diet 
low in fat and protein and high in vitamin E, selenium, vitamin A, and fiber (32). Synthetic 
retinoids are able to prevent azoxymethane-induced intestinal carcinogenesis in rats (53), 
although natural and synthetic retinoids have little effect on colon carcinogenesis iduced by 
aflatoxin and dimethylhydrazine (73). The few studies on lixer carcinogenesis indicated that 13-cis 
retinoic acid was highly effective in reducing the incidence of liver tumors induced by 3-methyl-4- 
dimethylaminoazobenzene (19,73). Similar findings have been reported for spontaneous hepatomas 
in mice given various doses of retynil ester (73). Several synthetic retinoids inhibited the development 
of azaserine-induced pancreatic tumors in rats when admistered during the promotional phase of 
carcinogenesis (59). In colorectal carcinoma cell lines ascorbic acid enhanced the antiproliferative 
effect of vitamin A (51), emphasizing their interdependence.
1.4. Antioxidants on colorectal epithelial cell proliferation, polyp recurrence and 
carcinogenesis: clinical trials in patients
The effect of carotenoid supplementation on precancerous lesions and cancer incidence has
been investigated in numerous clinical trials in the last two decades. Smaller trials in human
suggest that antioxidants can reduce colorectal epitethelial cell proliferation. Vitamin A, 
combined with ascorbic acid, a-tocopherol, furthermore selenium caused a significant reduction 
in the labeling index (LI) of the upper colonic crypts and the decrease in polyp recurrence in 
colorectal adenoma patients (14,15,16,23,65,95,103). Polyp formation could not be inhibited in 
larger full-scale trials (24,34,131) (details in discussion).
Prospective studies, including the particularly conclusive Basle study, Finnish cocort study, 
demonstrated that lower levels of retinol and carotene at entry were associated with a significantly 
increased relative risk for bronchus cancer and all other cancers (110,118,119) (details in 
discussion).
Few studies indicated a positive correlation between carotene intake and carcinogenesis. In the 
Jj-Carotene ana Aetinoi ntiicacy inai j o-caiuicnc mg; dllu vacuum
000 IU) were supplemented for patients with high risk for lung cancer (cigarette smoking 
history or asbestos exposure), it was finished because of the results of the Alpha-Tocopherol, 13- 
Carotene Cancer Prevention Study (ATBC) (39,40).
There was an increase in cardiovascular disease and lung cancer mortality among those 
assigned the supplementation combination.
In the Physicians Health Study (PHS) (120) US male physicians were randomized to alternate 
daily 50 mg 13-carotene and 325 mg Aspirin, both active treatment, or both placebo. There was 
no significant effect of 13-carotene on total cancer incidence.
Numerous problems (1,10,41,126) have been pointed out with these three studies, see detailed in 
discussion.
1.5. Prevalance and importance of the checked GI diseases
Upper gastrointestinal (GI) ulceration from drugs and inflammatory bowel diseases (IBD) as 
well as GI malignancies are relative common GI pathologies which have an appreciable GI
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mortality and morbidity. Furthermore, the role of environmental, genetic and nutritional factors 
in the aetiology of various cancers and other GI disorders emphasizes the importance of 
research in these GI conditions (101).
It has long been recognized that the relatively high incidence of GI ulceration arises from a 
variety of causes, among them stressful conditions, ulcerogenic drugs, infections, smoking and 
high intake of alcohol (91). While the incidence of peptic ulcer disease continues to be high, the 
international trend is, overall, towards a moderate decline (despite some fluctuations in reported 
statistics in some countries) except in individuals above 60 years of age where the incidence is 
increasing. Silent, or asymptomatic peptic ulcer disease which is evident in about 10% of 
patients is of particular importance because it often has a fatal outcome (101).
About 10% of the total Hungarian population suffer from peptic ulcer disease during the life span. 
It is true that the peak of disease incidence in patients (including males and females) appears after 50 
years of age, however, the costs of therapy are extremely high, though we still do not know exactly 
how much (91).
The non-steroidal antiinflammatory drugs (NSAlDs) are widely used in medical treatment for 
decrease of inflammatory and pain processes in patients, however, these compounds cause 
often gastrointestinal mucosal damage (Hr back diffusion, hemorrhage, bleeding) and different 
GI complains (dullness, epigastrial pain, vomitig) in a significant group of treated patients (78). 
The extent of NS AID consumption increased significantly in the Hungarian population suffering from 
different joint diseases. The number of patients who consumed NSAIDs treating their joint diseases is 
about 2-3 millions (20-30% of the nation) It is unambiguous that the number of patients suffering 
fromNSAIDs-induced gastrointestinal mucosal damage increased in the last decade (91). This fact is 
enough for doing research in this field.
GI mucosal lesions induced by NSAIDs are considered to involve multiple pathogenic 
elements, such as deficiency of prostaglandins (PGs), gastric hypermotility, disturbances in
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microcirculation, oxygen tree radicals, neutrophil activation and direct damaging effect on the 
gastric mucosa (weak vs strong acid-induced physico-chemical properties, like salicylic acid) 
(78,125). However, these components closely interact with each other and it would be difficult 
to determine which pathogenic element is of prime importance in the ulcerogenic response to 
NSAIDs. Indeed, neutrophil activation is caused by alteration of arachidonic acid metabolism, 
such as PG deficiency; gastric hypermotility leads to microcirculatory disturbances, resulting 
enhancement of neutrophil adherence to the vascular endothelium; and the production of oxygen 
radicals is brought about by neutrophil-endothelium cell interaction as well as haemodynamic 
alterations due to gastric hypermotility (125).
Nowadays, the extents and ratio of cyclooxigenase 1 (Cox-1) and cyclooxigenase 2 (Cox-2) 
inhibition are aominamiy in me international interesting ^ , / o y  me extern oi actions ui 
NSAIDs on COX 1. and 2. inhibition can be separated from each other experimentally, but we 
don’t have enough concrete data on the NSAIDs induced decrease of gastric mucosal blood 
flow (GMBF) in patients, however, it’s sure that it’s extent can not reach such level to be able 
to produce a real tissue hypoxia in the gastric mucosa (78).
Studies performed in animals can improve us to understand the mechanisms of GI mucosal 
damage and help in prevention. The presence of tissue hypoxia has been suggested as one of the 
main aetiological factors in the development of gastric mucosal injury (in acute ulcer phase and 
in other injuries in later phase) based on the basic physiological blood flow observations of 
Menguy et al (66-69).
A wide biochemical-pharmacological approach of ulcer disease has been applied in our 
Department in the last three decades (Mózsik et al.) (80,84,85,87,89) and this shift couid be 
observed in international research.
A special experimental approach to this problem has been established by the simultaneously 
carried out measurements of the biochemical compounds of membrane-bound ATP-dependent
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energy systems such as adenosine triphosphate (ATP), adenosine diphosphate (ADP). adenosine 
monophosphate (AMP) and cyclic adenosine monophosphate (cAMP) which gives an excellent 
biochemical „cross-section” of the target (stomach) organ together with lactate level 
(80,84,85,87,89).
The energy is stored in form of ATP in the gastric mucosa and the measurement of it’s actual 
tissue level informs us about the dynamic equilibrium between the ATP resynthesis and 
breakdown. The gastric mucosal ATP can be splitted in direction of ADP (by membrane 
ATPase) or cyclic AMP (by adenylate cyclase) liberating a free energy source for the tissue 
functions, while ADP and cAMP transforms to AMP supplying further energy liberation. AMP 
is a common energy storing adenosine compound originating from both pathways of ATP-ADP 
and a T P-caívLP oreaKUOwns (jransiormationsj. i ne uoeraieu eneigy is useu 101 me icguiauun 
of the different functions of the cells (80,84,85,87,89).
When the energy of different cellular functions originates from the gastric mucosal ATP 
breakdown, however, the results of activity of plasma membrane enzymes (membrane ATPase, 
adenylate cyclase) need to recognise in the changes of mucosal ADP, cAMP and AMP. 
Furthermore, different biochemical parameters can be calculated from the values of ATP, ADP, 
AMP: a) adenylate pool (ATP+ADP+AMP),
b) ratio of ATP/ADP and
c) „energy charge” {(ATP+0.5 ADP) / (ATP+ADP+AMP)} (82).
The value of energy charge is theoretically 1, when all of adenosine compounds are in 
phosphorylated form, and 0, when these compounds are in dcphosphorylated form (2)
After the basic observations of Menguy et al. (66-69), experimental and clinical researchers 
accepted these results as a strong correlation existing between the decrease of gastric mucosal 
blood flow and the decrease of gastric mucosal ATP level was considered to be a consequence 
of tissue hypoxia in the gastric mucosa (without presence of any scientifically proved
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arguments) (82). The biochemical measurement of the decrease of gastric mucosal ATP is not 
enough proof for the existence of tissue hypoxia alone, because the simultaneous elevation of 
tissue lactate is also basically necessary (82). The biochemical measurements of adenosine 
compounds offer an excellent biochemical research information on the extent of tissue 
oxygenation, when the observations are simultaneous from the same tissue sample. 
Furthermore, the existence of tissue hypoxia can be characterized well by the extremely low 
values o f tissue ATP, "energy charge" and increased levels of tissue lactate (78,82).
It is very important to emphasize that the observations of Menguy et al. were carried out in 
rats with hemorrhagic shock (66-69).
Earlier Davenport proved that weak acids induce gastric FT backdiffusion in presence of a 
strong -  like HU -  acicl (2u,2 I). Later Mozsik et ai. aemonstraieu me uecreaseu uieaKuuwn of 
adenosine triphosphate (ATP) into adenosine diphosphate (ADP) in rats treated with sodium 
salicylate plus pylorus-ligation (81), while it’s value increased only in pylorus-ligated rats (80). 
These and other observations proved the role of ATP dependent energy systems in the 
development of gastric hyperacid secretion in this experimental model.
Na-salicylate and indomethacin are both NSAIDs, however, their actions are significantly 
different, e g. salicylate acts as week acid, meanwhile, indomethacin produces inhibition of 
prostaglandin synthesis (75,77,83). These previous data suggest a significant difference in the 
metabolism of the stomach, in time of development of the gastric mucosal damage produced by 
sodium salicylate and indomethacin (20,21). However, we have only few data on drugs-induced 
intracellular metabolic changes in the G1 mucosa, therefore our aim was to investigate this 
matter on the membrane-bound ATP dependent energy systems (ATP-ADP, ATP-cAMP) and 
to study the changes in the feedback mechanisms between them.
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The incidence of IBDs is distinctly on the rise in Europe and USA though few studies 
consider this fact partly to be the consequence of improved efficiency in their diagnosis (71). It 
is true that with a total number of approximately SO illnesses per 100 000 inhabitants they are 
comparatively rare but these illnesses are not only a burden for the individual suffer but also put 
them under considerable psychological strain. The aetiology of IBDs still remains unclear. 
Although hereditary factors, microorganisms harmful to the mucosa and certain nutritional 
(eating) habits are assumed to be causal factors there is a little hard evidence to substantiate 
these assumptions (50,127). The familiar association of IBDs, reinforced by the demonstration 
of increased incidence of both Crohn’s disease and ulcerative colitis in monozygotic twins, is 
quite compelling evidence for an inherited component in the aetiology of both these diseases
provided interesting data and may well prove additional factors in the predisposition to IBD. Of 
the HLA associations observed, that for the DR2 system is relatively strong. Within this system, 
however, there appear to be variations that may be due to ethnic origins (e.g. high frequency of 
DRB 1.1502 alleles in Japanese and Jewish patients with ulcerative colitis but not in white non- 
Jewish subjects) (50,111).
Crohn’s disease is frequently complicated by various nutritional disturbances (17,55). 
Although it is important to correct these disturbances in treating of CD patients, the nutritional 
status of CD patients has been poorly documented, especially concerning vitamin status. Among 
various reports of vitamin A deficiency in different gastrointestinal and liver diseases (49,134), 
relatively few studies have investigated CD (30, 141). There has been inadequate documentation 
of the prevalence of vitamin A deficiency in patients with CD who are a population at a risk of 
protein malnutrition and fat malabsorption as a result of diseased or resected small bowel. No 
observations can be found in the literature describing the changes of all serum carotenoids in 
patients with IBD and GI cancer.
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Colorectal adenocarcinoma is the second most common malignancy in Europe and the USA 
and leads to considerable mortality (13,56). The disease is rare in Asia and Africa, this 
difference is thought to be largely environmental rather than racial. 45% of all G1 malignancies 
is colorectal compared with 25% stomach cancer, 15% pancreatic cancer, 11% esophageal 
cancer and 4% liver and bile duct cancer in West-European Countries (46). The prevalence of 
GI cancers is increasing in Hungary except of gastric cancer. The incidence of colorectal cancer 
increases with age, the average age at diagnosis is between 50 and 60 years (56).
Colorectal cancer has multifactiorial aetiology, numerous environmental and genetic aspects 
have been investigated. It is estimated that perhaps 35% (range 10-70%) of all cancer mortality 
in the United States could be attributable to dietary factors (99,136). Ecologic and migration 
studies indicate the importance ot environmental tactors in colon cancer (lusj. Diet appears to 
have a particularly strong association with occurence of this cancer, and thus it offers promise 
for intervention (99,136). The observation that higher colon cancer mortality rates occures in 
the countries where meat and fat was higher led to the hypothesis that these food items 
contributed to an individual's risk of developing colon cancer and was a stimulus for the current 
interest in dietary' intake in most analytic studies of the etiology of colon cancer (100). The 
oldest hypothesis asserts that fat intake increases bile acid production, ultimately increasing the 
exposure of the bowel mucosa to the toxic, trophic and cancer promoting effects of bile acids. 
The capacity of colonic flora to transform bile acids into potential carcinogens has been found to 
be greater in populations with high rates of colon cancer and among meat-eating populations 
than in vegetarian populations (100). A more recent hypothesis is the cooked food hypothesis. 
High-fat diets content greater amounts of carcinogenis heterocyclic amines (from meat proteins) 
and promoters as a consequence of cooking at high temperature (cooking in fat produces higher 
temperature than cooking in water) (18) A third and recent hypothesis is that high 
consumption of meat, particularly red meat, may increase fecal concentrations of iron, which
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catalyses oxidative reactions, leading to increased lipid peroxidation and oxidative DNA damage 
and to an increased risk of colorectal cancer (3). Furthermore the protective role of vegetable 
and fruit consumption, dietary fibers, calcium, vitamin D and the potential carcinogenic effect of 
succrose have been proved in the last decades (99).
The role of dietary components is well known in another types of G1 malignancies also. 
Consumption of salted, pickled and smoked foods have been associated with increased risk of 
gastric cancer in case-control studies (31). The strong, consistent inverse association between 
consumption of fruits and vegetables clear. Relatively high intake of 13-carotene and vitamin C is 
consistently associated with reduced risk of gastric cancer, the Basle study found a negative 
correlation between serum carotene levels and risk of gastric cancer. Similar results were found 
in case of esophageal cancer (j l ).
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2. AIMS
The aims of these thesis were: 1. To prove further intracellular effects of carotenoids on the 
membrane-bound ATP-dependent energy systems in a well identified animal experiment and 2. To 
measure serum levels of carotenoids (vitamin A, lutein, zeaxanthin, a-, 3-carotene, a-, 3- 
cryptoxanthin) with or without the presence of vitamin A activity in patients with different 
gastrointestinal acute and chronic inflammations, precancerous and malignant diseases.
2.1. The investigation of NSAID induced gastric mucosal damage in Na-salicylate and IND 
treated rats
2.1.1. Gastric mucosal damage (number and severity of mucosal lesions) and changes in 
gastric secretory responses
2.1.2. To check the energetic changes in gastric mucosa
2.1.3. The investigation of the protective effects of vitamin A and fi-carotene in IND- 
induced ulcer model
2.1.3.1. The effect of vitamin A and fi-carotene on number, severity of gastric mucosal 
lesions and gastric secretory responses
2.1.3.2. Vitamin A and fi-carotene induced changes in gastric mucosal energy systems
2.2. Changes of serum carotenoid levels in different GT diseases (human observations)
Few and contradictious data can be found in the literature related to the possible 
changes of serum levels of carotenoids in different human diseases (9,11,34,110, 117- 
119), therefore we checked these parameters in the following GI pathological
conditions:
2.2.1. G1 inflammatory diseases
2.2.1.1. Gastritis (with and without Helicobacter pylori colonisation)
2.2.1.2. Crohn's disease
2.2.1.3. Ulcerative colititis
2.2.2. Patients with hepatitis and cirhhosis (HCV and alcoholic)
2.2.2.1 Patients with alcoholic hepatitis
2.2.2.2 Patients with 11CV hepatitis
2.2.2.3 Patients with alcoholic cirrhosis
2.2.3. Coioreciai poiyps <wnii dinerem  insiuiogicai dasMiwiiiiun',;
2.2.4. Malignant GI diseases
2.2.4.1. Esophagus carcinoma
2.2.4.2. Gastric adenocarcinoma
2.2.4.3. Pancreas adenocarcinoma
2.2.4.4. Hepatocellular carcinoma
2.2.4.5. Colorectal adenocarcinoma
3. MATERIALS AND METHODS
3.1. The animal experiments were carried out random on both sexes of CFY (Sprague- 
Dawley) strain rats (LATI, Gödöllő, Hungary), weighing 180 to 210 body weight. The animals 
were fasted 24 hr before the experiments, but water was allowed ad libitum.
The animals were separated into different groups and went over different surgical procedures 
and pharmacological treatments. The observation periods were done at 4 h in all groups of 
animals, meanwhile the different surgical interventions and the intragastric and systemic 
treatments were done at 0 hr of the observations. The following experimental groups were 
created:
3.1.1.group A: sham-operation (laparatomy) was carried out (control group);
3.1.2. group 11: pyloric ligation was carried out alone;
3.1.3. group C: pyloric ligation was done, the animals received 2 ml saline solution
intragastrically (i.g.);
3.1.4. group D: the treatment of animals was the same that in group B, however they 
received i.g. 200 mg/kg sodium salicylate dissolved in 2 ml of 150 mmol/L HC1;
3.1.5. group E: the rats went over pyloric ligation (as in group B) and received 2 ml saline 
solution i.g, and furthermore were treated with 20 mg/kg indomethacin s.c. The animals 
received saline solution+indomethacin treatment immediately after surgery;
3.1.6. group F: animals received 20 mg/kg indomethacin (at the onset of observations) 
without any surgical intervention;
3.1.7. group H: the treatment of animals was the same as in group F and they received 
vitamin A or (3-carotene (in doses of 0.1-1.0-10 mg/kg) per os.
Animals in all groups received 2 ml saline solution subcutaneosly to protect them from 
dehydration. The animals were sacrified at 4 h after the surgical procedure and the 
pharmacological treatments, when the gastric secretory responses (volume and acid output) and
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gastric mucosal lesions were noted The biochemical observations were carried out from the 
homogenate of gastric mucosa at the end (4h) of the observations.
The tissue levels of ATP, ADP, AMP, and lactate were measured enzymatically (Boehringer 
Ingelheim. Germany), while tissue level of cAMP by RIA (Beckton-Dickinson, Orangeburg, 
USA). The protein content was assayed by the method of Lowry et al (60). The ratio of 
ATP/ADP, the values of adenylate pool (ATP+ADP+AMP) and the „energy charge” 
{(ATP+0.5 ADP) / (ATP+ADP+AMP)} were calculated (88).
The gastric secretory' responses (volumes, acid output) were measured in the 4h pyloric 
ligated rats. The volume of gastric secretion was expressed in ml/100 g body weight / 4 h while 
the gastric acid secretion in pE/100 g body weight / 4 h. The number of acute haemorrhagic 
mucosal lesions was counted, wnne me seventy was evaiuateu Dy a semiquanmauve scoring 
system, described previously (88) in a blinded fashion without knowledge of previous treatment 
A computerized planimetric method was also used in part of the study to confirm the evaluation 
of lesions and a close correlation (r = 0.92, p<0.01) was found between these two methods 
(118). The gastric mucosal lesions were expressed as number and severity (means+/- SEM). 
The parametric results were mathematically evaluated by Anova test, while semiquantitative 
results (ulcer severity) by Mann-Whitney’s test.
3.2. Human observations: carotenoids in human serum samples were measured with high 
pressure liquid chromatography (HPLC) method (25). We measured the serum level of vitamin 
A, lutein, zeaxanthin, alfa- and beta-cryptoxanthin, alfa- and beta-carotene.
Preparation of samples for HPLC measurements : 2 ml of the serum sample was shaken with 2 
ml of 96% ethanol for 2 min., following by an extracting with 3 ml of hexane. The mixture was 
centrifuged for 10 min.. As an internal standard canthaxantin was added to the removed 
homogenous organic phase. Then it was evaporated to dryness in vacuum, and the residue was
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dissolved in the mixture of 300 p! methanol and SO pi dichlormethane. 50 p! of this solution was 
injected. The chromatographic system consisted of a gradient former Model 250 B (Gynkotec, 
Germany), HPLC pump Model 300 B Glenco injector (Gynkotec,Germany), and a time 
programmable TIV-vis detector Model 166-2. eciuipped with Gold chromatoeranhv software 
(Beckmann, USA). The column was 150x4.6 mm packed with Chromsil-C. 0.186 mm not 
endcapped reversed phase packing. The eluent was 3% (v/v) water in methanol (A), methanol 
(B) and 40 % (v/v) dichlormethane in methanol. The flow rate was 1.5 ml/inin.. The gradient 
program was 100% A 30 sec., to 100% B in 3 min., to 100% C in 4 min.(linear steps). The time 
program of wavelength was 325 nm for 3.5 min.(detecting vitamin A), then 450 nm (detecting 
other carotenoids). Quantification: The chromatograms were evaluated quantitatively by relating 
the peak areas of the individual compounds to that canthaxantin used as internal standard, the 
ratios of the molar extinctions of the authentic samples to that of canthaxantin were employed 
as correction factor of the detector signals.
The results were given in pmol/liter. The results of 47 healthy persons (24 males, age: 50±12 
years, 20 females, age: 49±10 years) were used as control values in the statistical analysis. The 
results were expressed as means±SEM. Anova test was used for the statistical evaluation.
The serum levels of patients with the following G1 diseases were checked:
3,2.1. Patients with GI inflammatory diseases:
3.2.1.1. 35 patients with gastritis (among them 24 with Helicobacter pylori colonisation)
(20 males, age: 37±15 years, 15 females 36±12 years);
3.2.1.2. 49 patients with an established diagnosis of CD (21 males, 28 females, their age 
ranged rom 17 to 51 years; means ± SD: 27.4±13.4 years) were included in this study. 
The duration between the onset of the symptoms and the measurement was 4.7±3.8 years 
The site of involvement was the small bowel only in 20 patients, the large bowel only in 7
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and both in 22. There were no patients with any previous history of intestinal resection 
All of the patients were free of any nutritional treatment, non of them was receiving 
vitamin A supplements. The Crohn’s disease activity (CDAI) index was higher than 150 in 
22 patients and lower in 28 patients (CDAI: Best et al, Gastroenterology 70:439- 
44,1970). The majority of them were out-patients and maintenance therapy was given 
them.
3.2.1.3. 35 patients years with ulcerative colitis (17 males, age: 35±15 years, 18 females 
age: 33±12). The majority of them were out-patients and maintenance therapy was given
them.
3.2.2. Patients with hepatitis and cirrhosis
3.2.2.1. 8 patients with alcoholic hepatitis (8 males, age 38±10 years);
3.2.2.2. 75 patients with chronic C hepatitis (45 males, age 42±14 years, 32 females age: 
38±12 years);
3.2.2.3. 25 patients with alcoholic liver cirrhosis (17 males, age 40±15 years, 8 females age: 
38±12 years);
3.2.3. Patients with adenomatous colorectal polyps (59 patients, 35 males, age: 59±15 years, 24 
females, age 62±13 years); 39 patients had tubular adenoma (10 with mild, 16 with moderate,
13 with severe dysplasia), 11 patients had villouse adenoma (4 with mild, 4 with moderate, 3 
with severe dysplasia) and carcinoma was found in the removed polyp in 9 cases The patients 
were separated into 4 groups depending on the grade of dysplasia
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3 2 4.98 patients with different types of gastrointestinal malignancy were checked The
majority of them were in a good general condition, only some of them had metastasis The
patients were divided into smaller groups depending on the localisation of their disease.
3 2.4.1. 8 patients with esophagus carcinoma (cc. planocellulare) (8 males, age: 60±10 
years);
3.2.4.2. 21 with gastric cancer (adenocc.) (16 males, age 64±12 years, 5 females age: 
68±10 years),
3.2.4.3. 10 patients with pancreas adenocarcinoma (6 males, age 56±11 years, 4 females 
age: 63±9 years);
3.2.4.4. 15 with hepatocellular carcinoma (8 males, age 60±8 years, 4 females age: 57±13 
years);
3.2.4.5. 44 patients with colon adenocarcinoma (26 males, age 66±16 years, 18 females 
age: 65±14 years);
The diagnosis was based on clinical, laboratory', endoscopic, radiographic and histological 
findings. The histopathological diagnosis was based on the World Health Organisation 
(WHO) classification (47), the histopathologists in the two medical centres were blinded to 
the serum results.
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4. RESULTS
4 1. Results in animal experiments
4 1.1. Gastric secretory responses and development of gastric ulcers in 4 hr pylorus- 
ligated plus sodium salicylate or indomethacin treated rats
The results are presented in Table I. and Figs 1-4. The gastric secretory responses were 
unchanged in pylorus-ligated rats without vs. with intragastrically applied 2 ml saline solution 
(group B vs. group C). When the animals received sodium-salicylate (group D) intragastrically 
then the volume of gastric secretory volume increased (p<0.001) meanwhile the gastric acid 
output decreased significantly (p<0.001). No significant changes were found in gastric secretion 
in pylorus ligated plus indomethacin (group E) vs. only pylorus-ligated rats (group B), however, 
gastric ulceration was tound in group b. the gastric secretory response aia not moairy me 
indomethacin induced gastric ulceration (group E vs. group F) with or without pyloric ligation.
Vitamin A and (3-carotene did not influence the gastric secretory' responses. After the co­
treatment of IND+vitamin A or [3-carotene (group H) the number and severity of IND-induced 
mucosal injury' decreased dose dependency (Figs. 1-4.).
These results clearly indicate both sodium salicylate and indomethacin produce gastric 
mucosal injury' in the same extent, however the changes in the gastric secretory responses 
(volume, acid output) are completely different. Furthermore the gastric secretory' responses 
(volume and acid output) are the same in only pylorus-ligated (group B), pylorus-ligated plus 
intragastrically 2 ml saline solution treated (group C) rats than those in pylorus-ligated plus 
intragastrically saline plus indomethacin treated group ([group E). These observations prove that 
the changes in the gastric secretory responses (volume, acid output) can be separated from the 
development of drug-induced mucosal damage (at least under these experimental 
circumstances).
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Table I. Gastric secretory response and gastric mucosal damage in the studied 
experimental groups of animals (means +- SEIM) (n=number of animals).
Groups of 
animals
(n)
(ml/100 gb.v
tion Acid output 
v./4h) (uEq/100 g b.w./4 h)
Number and severity 
of gastric mucosal lesions
A (n=20)
B (n= ll) 1.9+-0.2 180+-20
C (n=l 1) 2.0+-2 NS 190+-20 NS
D(n=10) 3 .1+-0.4'** 110+-15 14.2+-1 27.2+-2.1’”
E (n=l 1) 2.2+-0. INS 140+-20 NS 17+-2 ^ 2 o + -r^
F(n=20) 19+-1+” 20+-T”
Abbreviations: Group A: sham-operated rats; group B: pyloric-ligated rats; Group C: pyloric- 
ligated rats+2 ml saline solution was given intragastrically; Group D: pyloric-ligated rats+200 
mg/kg souium sancyiate aissoivea in i  ml or 15U mmol/1 HU; Uroup E: pyloric ligation+2 ml 
saline solution intragastrically+20 mg/kg indomethacin sc.; Group F: animals received 20 mg/kg 
indomethacin (at the onset of observations) without any surgical intervention;
P values were calculated between the Group C vs. D and Group C vs. F. Abbreviations: NS, 
not significant; +++: P<0.01
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Figs. 1-4.: Number and sceerity of gastric mucosal lesions in animals treated with IND, 
iND+vitamin A or B-carotene (means+SEM).
Fig. 1. Number of gastric mucosal lesions in animals treated with IND+vitamin A 
(means±SEM).
QZj IND+10 mg/kg vit.
j ig. 2. Severity of gastric mucosal lesions in animals treated with IND+vitamin A 
(means±SEM).
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Fig. 3. Number of gastric mucosal lesions in animals treated with IND+B-carotene 
(means±SEM).
Fig. 4. Severity of gastric mucosal lesions in animals treated with IND+B-carotene 
(means±SEM).
41.2 Sodium salicylate and indomcthacin induced metabolic changes in the gastric 
mucosa in 4 h pylorus-ligated rats
The biochemical results in sodium salicylate and indomethacin-treated animals are presented in 
Table II and Figs 5-18
The gastric mucosal ATP decreased significantly in the group B (p<0.001), C (p<0.001), 
D (pO.OOl), E (pO.OOl) and F (pO.OOl). The gastric mucosal ADP increased in the groups B 
(pO.OOl), C (p<0.001) and F (p<0.001), while it’s value decreased in groups D (p<0.001) and E 
(pO.OOl). The gastric mucosal AMP was decreased in all (B,C,D,E,F) groups. The gastric 
mucosal cAMP was also decreased in all (B,C,D,E,F) groups. The values of adenylate pool 
(ATP+ADP+AMP) was decreased in all (B,C,D,F) groups. The values of energy charge are 
between 0.4 and 0.5. The ratio of ATP/ADP decreased significantly m group b fp^-u.uuij, w 
(p<0.001), E (pO.OOl) and F (p<0.001), meanwhile it’s value was increased significantly in group 
D (Table II.).
After the co-treatment of TND+vitamin A (0.01-0.1-1.0-10.0 mg/kg body weight) or beta- 
carotene (0.01-0.1-. 1.0-10.0 mg/kg) (group H), the tissue level of ADP decreased dose- 
dependently, meanwhile the tissue level of ATP, ATP/ADP, cAMP, AMP increased significantly 
and dose-dependently, however the adenylate pool showed an increasing tendency by the 
administration of increasing dosage of vitamin A and beta -carotene. The value of energy charge 
did not change significantly by the application of vitamin A and beta-carotene (Figs. 5-18.)
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Table TI.
Changes in the gastric mucosal biochemical parameters in the groups mentioned in Table 1. The biochemical results were expressed as 
means +- SEM, n indicates the number of animals
Groups of animals
Measured
and calculated
experimental
parameters
A
(n=20)
B
(n=ll)
C
(n=H)
D
(n=20)
E
(n=H)
F
(n=20)
ATPX 11.1+-0.4 2.3+-0.2444 3.6+-0.8+++ 6.8+-0.4 ++ 5.7+-0.3444 4.6+-0.34 4
ADPX 13+-0.4 22+-1444 16.9+-0.6444 8+-0.64' 1 1+-0.2444 17.8+-0.4444
AMPX 14.1+-0.5 4.8+-0.3444 9.1+-0.3444 7.3+-0.4 44 5.2+-0.2444 10.5+-0.3444
Ratio of ATP/ADP 0.85+-0.05 0.11+-0.01444 0.21+-0.01444 2.1+-0.0 i44 + 0.52+-0.024'"o^ g+ ^ .o!4*1
„Adenylate pool”4 38.3+-1 29.1+-0.8444 29.6+-0.8+++ 32.1+-0. P44 22.+-0.7444 32.1+-0.6444
„energy charge” 0.46+-0.02 0.48+-0.02 0.4+-0.02444 0.49 i-0. )2" 4 0.51+-0.02 0.42+-0.01 44
cAMI)XX 3.35+-0.03 0.73+-0.0144+ 1.05+-0.02444 1.08+-0.01444 1.47+-0.014’4 1.34+-0.02 44
Abbreviations: Group A: sham-operated rats; group B: pyloric-ligated rats; Group C: pyl >ric-ligated rats+2 ml saline solution was given intragastrically; 
Group D: pyloric-ligated rats+200 mg/kg sodium salicylate dissolved in 2 ml of 150 mmol/1 HC1; Group E: pyloric ligation+2 ml saline solution 
intragastrically+20 mg/kg indomethacin sc.; Group F: animals received 20 mg/kg indome hacin (at the onset of observations) without any surgical 
intervention;
x=nmol/mg gastric mucosal protein 
xx=pmol/mg gastric mucosal protein
P values were calculated between the results obtained in group A vs. others obtained in the different groups.
Figs. 5-18. Changes in biochemical parameters in saline-, IND, IND+vitamin A or ÍJ- 
carotene treated groups
1 Saline treated 
3 3  IND-treated
ÜS IND+OJ mg/kg vit A 
^ 3  IND+1 mg/kg vit. A
Fig. 5. Gastric mucosal ATP level in saline-, IND, IND+vitamin A treated groups 
(means+SEM, nmol/mg gastric mucosal protein)
Fig. 6. Gastric mucosal ADP level in saline-, IND, IND+vitamin A treated groups
(means+SEM, nmol/mg gastric mucosal protein)
Fig. 7. Gastric mucosal AMP level in saline-, IND, IND+vitamin A treated groups 
(means±SEM, nmol/mg gastric mucosal protein)
s :To, significant
Fig. 8. Gastric mucosal ATP/ADP ratio in saline-, IND, IND+vitamin A treated groups
(meanstSEM)
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Fig. 9. Gastric mucosal adenylate pool in saline-, 1NL), ii\D-i-vitamm a  ireaieu groups 
(means+SEM)
Fig. 10. Gastric mucosal energy charge in saline-, IND, IND+vitamin A treated groups 
(means+SEM)
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Fig. 11. Gastric mucosal cAMF level in saline-, 1JNU, lfN D-t-vitamin a  treated groups 
(means±SEM, pmol/mg gastric mucosal protein)
Fig. 12. Gastric mucosal ATP level in saline-, IND, IND+beta-carotene treated groups
(means±SEM, nmol/mg gastric mucosal protein)
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Fig. 13. Gastric mucosal ADP level in saline-, IND, IND+beta-carotene treated groups 
(means+SEM, nmol/mg gastric mucosal protein)
Fig. 14. Gastric mucosal AMP level in saline-, IND, IND+beta-carotene treated groups
(means+SEM, nmol/mg gastric mucosal protein)
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Fig. 15. Gastric mucosal ATP/ADP ratio in saline-, IND, IND+beta-carotene treated 
groups (means±SEM, nmol/mg gastric mucosal protein)
Fig. 16. Gastric mucosal adenylate pool in saline-, IND, IND+beta-carotene treated
groups (means+SEM, nmol/mg gastric mucosal protein)
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Fig. 17. Gastric mucosal energy 
(means±SEM, nmol/mg gastric
4.2. Human observations
4.2.1. Patients with inflammatory GI diseases (Figs. 19-24).
Significant changes were not found between the results of healthy volunteers and patients 
suffering from gastritis with or without Helicobacter pylori colonisation.
Five of the seven measured carotenoids were depleted in CD patients (107), the serum 
levels of vitamin A, luthein, zeaxanthin, a- and P-carotene were significantly lower in 
patients than in the control group (zeaxanthin: p<0.001; vitamin A, lutein, a - and P- 
carotene: p<0.01).
The serum level of a - and P-cryptoxanthin showed a slight, but not significant decrease.
A strong correlation was found between vitamin A level and CDAI (r=0.7). There was no 
correlation between the duration ol symptoms ana caroienoiu simus. We did nwi fh.d 
significant differences in the serum levels of carotenoids depending on the site of 
involvement.
The patients had lower mean serum albumin and cholesterol levels then the controls (not 
significant), but there was no correlation between these parameters and vitamin A level 
(Table IV.).
We found a significant decrease in the serum level of vitamin A (p<0.001) and P-carotene 
(p<0.001) in patients with ulcerative colitis (108), a moderate, but not significant decrease 
in the serum level of lutein and zeaxanthin, all of the other checked carotenoids were in the 
normal range. There was no correlation between the duration of symptoms and carotenoid 
status. We did not find significant differences in the serum levels of carotenoids depending 
on the site of involvement. Neither in patients with ulcerative colitis, nor in CD patients 
were found differences depending on gender.
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Fig. 19. Serum level of vitamin A in patients with gastritis, alcoholic and HCV 
hepatitis, aicohoiic iiver cirrhosis, Ciolin's disease and ulcerative colitis 
(expressed in percent values of healthy subjects as means±SEM)
Fig. 20. Serum level of zeaxanthin in patients with gastritis, alcoholic and HCV 
hepatitis, alcoholic liver cirrhosis, Crohn’s disease and ulcerative colitis 
(for further explanation see text on Fig. 19.)
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Fig. 21. Serum k \t!  of cí-carotene in patients with gastritis, alcoholic and HCV 
hepatitis, alcoholic liver cirrhosis, Crohn’s disease and ulcerative
Fig. 22. Serum level of (3-carotene in patients with gastritis, alcoholic and HCV 
hepatitis, alcoholic liver cirrhosis, Crohn’s disease and ulcerative colitis 
(for further explanation see text on Fig. 19.)
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Fig. 23. Serum level ofluíein in patients with gastritis, alcoholic and HCV hepatitis, 
alcoholic liver cirrhosis, Crohn’s disease and ulcerative colitis 
(for further explanation see text on Fig. 19.)
Fig. 24. Correlation between vitamin A level and CDAI in patients with Chrohn’s
disease
4.2.2. Patients with colorectal polyp (Figs. 26-30.)
The serum levels of vitamin A (p<0.01) and zeaxanthin (p<0.01) were significantly lower in 
patients with different histological types of colorectal poiyp, than in the control group 
(106). The most significant decrease was found in patients with adenocarcinoma in the 
polyp.
The serum level of beta-cryptoxanthin and beta-carotene showed a slight, but not 
significant decrease.
The serum level of lutein and alfa-cryptoxanthin did not differ significantly from the 
control values.
Carotenoids are fat soluble therefore the absorption of these materials depends on fat 
absorption. In case of malnutrition or malabsorption the serum carotenoid levels will be also 
lower than the normal values. To preclude the possibility of malabsorption and malnutrition, 
the body mass index (BMI) of the patients, the serum level of cholesterol, albumin, total 
protein and haemoglobin were checked. Neither in patients with ulcerative colitis nor in 
patients with colorectal polyp differed these parameters significantly from that of controls 
(Table IV.), these parameters did not indicate malabsorption or malnutrition.
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Vitamin A (%)
Fig. 26. Serum vitamin A levels in patients with different histologically graded 
colorectal polyps (for further explanation see text on Fig. 19.)
Fig. 27. Serum zeaxanthin levels in patients with different histologically graded
colorectal polyps (for further explanation see text on Fig. 19.)
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Fig. 28. Serum a-carotene levels in patients with different histologically graded 
colorectal polyps (for further explanation see text on Fig. 19.)
Fig. 29. Serum [3-carotene levels in patients with different histologically graded
colorectal polyps (for further explanation see text on Fig. 19.)
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The serum level of P-cryptoxanthin and P-carotene showed a slight, but not significant 
decrease in patients with pancreas and colorectal adenocarcinoma, significant decrease was 
found in not one of the checked diseases. The serum level of lutein, a-carotene and P- 
cryptoxanthin did not differ considerably from the control values.
Significant differences were not found between the results of males and females, neither 
in the control group, nor in the patients with adenoma therefore we did not calculate the 
results of genders separated. The checked serum parameters did not indicate malabsorption 
or malnutrition (Table IV.).
CSS Cast™ cc.
Fig. 31. Serum levels of vitamin A in different human malignant GI diseases 
(for further explanation see text on Fig. 19.)
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The serum level of P-cryptoxanthin and P-carotene showed a slight, but not significant 
decrease in patients with pancreas and colorectal adenocarcinoma, significant decrease was 
found in not one of the checked diseases. The serum level of lutein, a-carotene and p- 
cryptoxanthin did not differ considerably from the control values.
Significant differences were not found between the results of males and females, neither 
in the control group, nor in the patients with adenoma therefore we did not calculate the 
results of genders separated. The checked serum parameters did not indicate malabsorption 
or malnutrition (Table IV.).
Fig. 31. Serum levels of vitamin A in different human malignant GI diseases 
(for further explanation see text on Fig. 19.)
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+++ = p<0 001, ++ = p<0 01, + = p<0 05, N .S
Fig. 32. Serum levels of zeaxanthin in different human malignant GI diseases 
(for further explanation see text on Fig. 19.)
Fig. 33. Serum levels of a-carotene in different human malignant GI diseases
(for further explanation see text on Fig. 19.)
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Fig. 34. Serum levels of P-carotene in different human malignant GI diseases 
(for further explanation see text on Fig. 19.)
Fig. 35. Serum levels of lutein in different human malignant GI diseases
(for further explanation see text on Fig. 19.)
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Changes of serum carotenoids in patients with different GI diseases (compared to the results of healthy subjects)
Table III.
VITAMIN A ZEAXANTHIN a-CAROTENE B-CAROTENE LUTEIN a-CRYPTO p-CRYPTO-
GASTRITIS
n=35 NS NS NS NS NS
XANTHIN
NS
XANTHIN
NS
C HEPATITIS 
n=75 u NS NS • NS NS NS NS
ALC. HEPATITIS 
11=8 NS NS NS NS NS NS NS
ALC. CIRRHOSIS 
n=25 w NS NS NS NS NS NS
CROHN’S DISEASE 
n—49 ii U u W NS NS
ULCERATIVE 
COLITIS n=35 m NS NS iii NS NS NS
COLORECTAL 
POLYP n=59 a u NS NS NS NS NS
ADENOCC.
IN POLYP n=9 m H i NS NS NS NS NS
ESOPHAGUS CC. 
n=8 a ii NS NS NS NS NS
GASTRIC CC. 
n=2 l a i NS NS NS NS NS
HEPATOCELLULAR 
CC. n=15 m m NS NS NS NS NS
PANCREAS 
CC. n= 10 NS 4, NS NS u NS NS
COLORECTAL CC. 
n=41 H i m NS NS NS NS NS
iii= p<0,001; ii=p<0,01; i=p<0,05; NS= not significant
Table IV.: BMI, serum cholesterol, albumin, total protein and hemoglobin levels in 
different groups of patients (means+SD)
BMI SE CHOL. SE ALB. g/1 TOTAL HGB
mmol/1 PROT. g/1 g/1
HEALTHY 24±4.4 5.6+1.25 39.9+4.23 75.6+7.18 139+18.
(n=47)
GASTRITIS (n=35) 25.3+4.8 5 81+2.1 40.9+5.01 72.2+6.2 135 ±12
C HEPATITIS (n=75) 23.5+5.9 5.45+1.46 35.8+1.75 68.54+6.77 130+14.3
ALC. I EPATITIS (n=8) 26.714.3 5,85+1.52 36.9+4.53 74.82+7.84 129.±18
ALC. CIRRHOSIS (n=25) 28.115.6 3.6+0.85 28.9+4.23 70.18+8.65 121+16
CD (n=49) 2213.8 4.64+0.71 32.9+4.25 71.15+9.56 122+10
ULCERATIVE 25.814.3 5.44+0.91 34.3+5.45 75.56+7.68 120+10
COLITIS (n=35)
COLORECTAL 26.916.8 5.84+1.21 37.8+3.23 72.18+6.23 135+7
POLYPOSIS (n=59)
ADENOCC.IN POLYP 26.516.4 5.73+1.22 41.3+4.96 73.45+9.78 139+14
(n=9)
ESOPHAGEAL 24.317.1 6.01+1.12 36.31+6.21 74.13+8.74 131+13
CC. (n=8)
GASTRIC CC. 23.515.8 5.86+1.26 42.9+4.95 69.25+7.68 126+15
(n=21)
PANCREAS CC. 22.214.2 5.62+0,89 39.9+5.58 67.65+5.84 114+18
(n=10)
HEPATOCELL. CC. 25.816.1 5.95+1.32 33.6+5.05 65.15+8.81 120.96+19
(n=15)
COLORECTAL CC. 24.915.1 6.01+1.32 34.9+4.53 71.45+8.88 125+20
(n=44)
5. DISCUSSION
Different experimental circumstances were used for the critical evaluation of physiological 
(volume of gastric secretion, acid output) and pathological (number and severity of gastric 
mucosal damage) changes in the membrane-bound ATP-dependent energy systems and the 
gastric mucosal damage produced ig. administration of sodium, salicylate (in dose of 700 
mg/kg dissolved in 3 50 mmol HC1) and by indomethacin (20 mg/kg sc. given).
The following main actions (mechanisms) were tested: a.) action of sc. administered 
indomethacin on the gastric mucosal damage (group A vs. F), b.) the possible role of gastric 
hypersecretion on the development of gastric mucosal damage (without application of any 
drug) (group A vs. B); c.) the increase of gastric volume (without any increase of gastric FT 
secretion) (group B vs. C), d.) the actions of sodium salicylate on the gastric secretory 
volume, acid output and mucosal damage (group C vs. D); f.) the effect o f indomethacin on 
the gastric secretory responses (volume, acid output) and on gastric mucosal damage in 4 hr 
pylorus-ligated rats (group C vs. E); g.) the comparison of the damaging effect of 
indomethacin without (group F) and with (group E) gastric hypersecretion; h.) the 
biochemical correlation (as members of membrane-bound ATP-dependent energy systems) 
in gastric mucosa or gastric physiological (pathological) events (group A vs. F).
The gastric hypersecretion (group C) alone can not produce gastric mucosal lesion, which 
is associated with an extremely increased ATP-ADP transformation (and with the decrease 
of ATP-cAMP transformation) (114), meanwhile it is inhibited by surgical vagotomy (117). 
If the animals are treated with ig. saline solution (2 ml) (group B) thereafter neither the 
gastric secretory volume nor the acid output will not change in comparison with only 
pylorus-ligated (group C) rats, furthermore the changes in ATP-dependent energy systems 
are the same. If animals received 200 mg/kg sodium salicylate ig. dissolved in 2 ml 150 
mmol/l ÍIC1, then the gastric acidity (output) decreased significantly (p<0.001), while the
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volume of gastric secretion increased (p<0.001) and gastric mucosal lesions appeared 
(group C vs. D). The tissue level of ATP was higher in sodium salicylate treated rats than in 
pylorus-ligated+ig. saline solution treated animals. Indomethacin (without any surgical 
intervention) produced gastric mucosal damage in association with similar changes in the
iigated+ig. with saline solution treated animals. It means that indomethacin increases the 
ATP-ADP transformation (in association to a decreased ATP-cAMP transformation). The 
indomethacin treatment (group E) did not modify the gastric secretory responses (volume 
and acid output) in pylorus-ligated animals in comparison those with only pylorus-ligated 
rats.
These results demonstrate that neither gastric secretory responses nor changes in the 
gastric mucosal ATP-dependent energy systems did not cause separatedly gastric mucosal 
injury. The significant part of gastric H+ diffused back, meanwhile the volume of gastric 
secretion (dominantly water) increased. Salicylic acid is a weak acid, and it’s dissociation is 
inhibited in the presence of HC1. The undissociated salicylic acid is able to absorb from the 
stomach and the gastric mucosa is precipitated in this way.
The mitochondrial ATP is a common substrate for membrane ATP-ase and for adenylate 
cyclase in presence of Mg+T (82,85,86,87) and furthermore, these enzymes can be 
stimulated or inhibited by various hormones, mediators and drugs (82,85,86,87).
The actual levels of membrane bound ATP dependent energy systems are as equilibrium 
their extens of ATP breakdown and of resynthesis. The tissue level of ATP resynthesis is 
impaired under the circumstances of tissue hypoxia which can be detected biochemically by 
the together presence of a: a significant increase in tissue level of lactate, and b: failure of 
ATP resynthesis due to impaired oxidative phosphorilation by tissue hypoxia. The
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significant decrease of tissue ATP level was observed alone in many experimental models, 
bul without any increase in the tissue level of lactate (see details in refeiences 82,85,87).
The measured ATP, ADP and cAMP (in case of normal oxidative phosphorilation) 
indicate the equilibrium between extents of ATP-ADP and ATP-cAMP transformations. 
These responses show thai a feedback mechanism exists between the two membrane-bound 
AlP-dependent energy systems. The system is characterized mainly by the following: a: 
ATP is a common substrate for both the membrane (Na"-K+ dependent ATPase and 
adenylate cyclase); b: drugs which stimulate membrane ATP-ase activity inhibit the 
transformation of ATP into cAMP by adenylate cyclase; c: drugs, mediators and hormones 
inhibiting membrane ATP-ase activity stimulate adenylate cyclase activity and vica versa, d: 
the increased transformation of ATP into ADP indirectly inhibits the transformation of ATP 
to cAMP; e: the decrease of transformation of ATP into ADP by various agents leads to 
indirect stimulation of the transformation of ATP to cAMP; f: the increase in ATP 
transformation to cAMP leads to an indirect inhibition of ATP into ADP (82), g: cAMP and 
AMP inhibit directly the transformation of ATP to ADP by inhibition of membrane ATPase 
(85); h: the inhibition of the transformation of ADP into cAMP is the result of the indirect 
stimulation of the transformation of ATP to ADP, i: the extent of cAMP transformation to 
cAMP through regulation of phosphodiasterase by drugs may regulate both ATP-ADP and 
ATP-cAMP regulation; j: the molar dose of drugs regulate the membrane ATPase are 
smaller molar concentrations then those effecting or modifying the adenylate cyclase activity 
(82,85,86,87).
The analysis of membrane-bound ATP-dependent energy systems in animals treated 
with sodium salicylate (group D) and indomethacin (group E) in pylorus-ligated rats 
indicate an increased extent of ATP-ADP transformation after indomethacin treatment in 
comparison with that of sodium salicylate treated animals. There is a limited (or decreased )
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metabolic adaptation in the ATP energy system after sodium salicylate treatment (79). The 
prostaglandin levels decreased after indomethacin treatment which is associated with a 
significant decrease of cAMP in the gastric mucosa. In the sodium salicylate treated animals 
decreased the metabolic adaptation significantly, meanwhile the ATP-ADP transformation 
increased in indomethacin treated animals, however PGs. decreased 
The results of membrane-bound ATP dependent energy systems were expressed as means 
(100 %) +/- SEM (%) in the control animals (group A). The changes of membrane bound 
ATP dependent energy systems were expressed in percent values (means+/- SEM) of 
control animals in other groups, and the p values were calculated between the controls (A) 
vs. others (B,C,D). this analysis of the results offered an excellent possibility to approach 
the final results produced by different extracellular and intracellular regulator}’ feedback 
mechanisms in the gastric mucosa. The careful analysis of the biochemical observations 
indicate that the first lines of ATP breakdown are in the levels of ATP-ADP and ATP- 
cAMP (because tissue level of lactate was unchanged in the gastric mucosa under these 
experimental circumstances). The extents of ATP-ADP transformation increased in pylorus 
ligated and alone IND-treated animals (B and D), while the extent of ATP-cAMP 
transformation was decreased in this group (in comparison of their extents in the control 
group). According to cellular biologists, the 60-75% of total cellular energy is used for the 
intact function of sodium and potassium pump system in the cells.
The noxious agents (Na-salicylate and IND) can modify the membrane bound ATP- 
dependent energy systems in different direct and indirect pathways. Both energy liberation 
pathways, namely ATP-ADP and ATP-cAMP, are significantly inhibited by sodium 
salicylate. These effects can be understood by a physiochemical property of the sodium 
salicylate because the extent of dissociation of a week acid (e.g. salicylic acid) is inhibited 
in presence of strong acid (HC! in pylorus ligated rats) (20,21). This undissociated week
(including membrane ATTase and as well as adenylate cyclase). The actual metabolic state 
of gastric mucosa in rats treated with sodium salicylate or IND differ significantly from each 
other.
Vitamin A and p-carotene prevented dose-dependcntly the IND-induccd gastric mucosa! 
damage in animals. Our results indicated that these compounds produce dose dependent 
changes of membrane-bound ATP- dependent energy systems.
After IND treatment the extent of ATP-ADP transformation increased significantly, 
while the ATP-cAMP transformation and the cAMP-AMP tarnsformation decreased 
significantly. When the animals were treated with vitamin A or beta-carotene then the 
extent of ATP-cAMP increased significantly, however the cAMP-AMP transformation 
increased.
These results prove that the mucosal protective effects of vitamin A and beta-carotene is 
a cAMP-dependent mechanism. On the other hand, these scavenger materials are kept a 
regulatory mechanism between the membrane-bound ATP-dependent adenosine 
compounds by the way of extra and intracellular pathways.
Previous studies havr proved that carotenoids have no inhibitory effects on gastric acid 
secretion neither in animals (42) nor in humans (48), however (3-carotene was able to 
prevent the gastric mucosal damage in different experimental models such as ethanol-, 
hydrochloric acid- or indomethacin-induced mucosal damage. The ulcer healing effect of 
vitamin A was proven in randomized, multicenter clinical studies (97). The 
gastroprotection induced by carotenoids does not depend on the presence of vitamin A 
activity, p-ionone ring, number of unsaturated links or chemical structure of terminal part 
of molecules (48,74). Moreover, the analysis of gastric mucosal antioxidant mechanisms 
and free radical generation during p-carotene-induced gastric mucosal protection
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suggested that the scavenger character of (3-carotene might partially explain its protective
Our investigations have shown the deficiency of certain serum carotenoids in different G1 
diseases. Five of the measured seven compounds were depleted in CD patients, while the 
serum level of vitamin A and (3-carotene decreased significantly in patients with UC, 
furthermore vitamin A deficiency has been proved in patients with HCV hepatitis and 
alcoholic cirrhosis. Vitamin A and zeaxanthin were depleted first of all in the serum of 
patients with colorectal polyp and different GI malignant diseases.
Plasma retinol levels fall only in case of exhausted liver reserves (vitamin A is stored 
almost entirely in liver), therefore the screening of serum levels is not the most sensitive 
marker of vitamin stores but it is a simple and informative method to check vitamin A 
deficiency (61).
Hypovitaminosis in CD patients may be induced by several mechanisms: poor intake, 
malabsorption, bacterial overgrowth of the small intestine and increased requirement of the 
inflammatory process (45,64,106). Also disturbed zinc metabolism might contribute to the 
pathogenesis of vitamin A deficiency because of the depression of protein synthesis and the 
depression of particular impaired synthesis of praealbumin and retinol binding protein (112). 
Former studies (45,64,102,112) and the other checked serum parameters, furthermore the 
correlation between serum vitamin A level and CDA1 indicate that our finding is 
unambigously a consequence of CD.
However, because many factors are related to the serum concentrations of vitamins, we 
are cautious in drawing any conclusions. We did not evaluate the vitamin intake in this 
study, therefore it is rather difficult to determine causal relationships - we could not
57
conclude which of the above mentioned factors was more important in decreasing of 
carotenoid 'levels.
Further studies, including the composition of vitamins in the diet and investigation of 
vitamin absorption are necessary to clarify the vitamin status in CD. These approaches seem 
to reveal more information to the necessity of intensive nutritional care concerning vitamins 
and, if necessary, as to the dose of replacement from the clinical point of view.
Although the laboratory parameters of UC patients did not indicate malnutrition, the 
decrease of carotenoids in the serum of patients is highly likely the consequence of the 
inflammatory process or poor intake.
The decrease of vitamin A level in patients with HCV hepatitis and liver cirrhosis may be 
the consequence of impaired storage capacity of the liver.
Significant decrease of vitamin A and zeaxantin was found dominantly in the serum of 
patients with different malignant gastrointestinal diseases (except of zeaxanthin in 
patients with pancreas adenocarcinoma). Similar results were found in cases of 
colorectal polyps with different histological stages. No significant changes were 
observed in the serum level of the other carotenoids.
It is rather difficult to determine causal relationships in the present study the based on 
these results but the decrease in serum level of vitamin A and zeaxanthin may offer 
relation of cause and effect between their serum levels and development of colorectal 
polyps and GI cancers in patients. Earlier the decrease of serum level of vitamin A has 
been emphasised in development of different malignancies (included GI malignancies) in 
Basle study and other prospective studies (110,118). Our study indicated the existence of 
the same negative correlation between the decrease of vitamin A and zeaxanthin in the 
patients’ sera vs. colorectal polyps and different GI carcinomas.
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These observations indicate:
of colorectal polyps, proceeding the progression of colorectal cancers,
2. It was surprising that the serum levels of vitamin A precursors (a- and (3-carotene) 
were normal in the patients with GI cancer and coiorectai polyps, when the serum level 
of vitamin A decreased significantly. At this moment we have no explanation why these 
provitamins are not able to transform into vitamin A (disorders of enzymatic 
transformation or decrease of vitamin A binding capacity, etc.). Probably these events 
are in the background why vitamin A decreased in the sera of patients with adenoma and 
GI cancer.
3. Accepting the fact that coiorectai polyps represent precancerous state for coion 
tumor and the same clinical correlation exists between carotenoids vs. colorectal 
diseases (polyps and cancers), furthermore between carotenoids vs. the other malignant 
GI diseases, the decrease of vitamin A and zeaxanthin may be one of the nutritional 
promoting compounds in the development of these diseases;
4. Zeaxanthin does not have vitamin A activity, so surprisingly the supposed 
preventive effect is not only vitamin A activitie’s consequence.
The effect of carotenoid supplementation on precancerous lesions and cancer incidence 
has been investigated in numerous clinical trials in the last two decades. I would like to cite 
several trials related to this topic, some of them support our thesis, the other part seems to 
be contradictious at first.
Four small trials in human suggest that antioxidants can reduce colorectal epitethelial cell 
proliferation. In a small randomized, placebo-controlled clinical trial in colorectal adenoma 
patients (n=4i), those given 30 000 IU vitamin A, 70 mg a-tocopherol plus 1000 mg
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ascorbic acid had a 45% greater reduction than those given placebo in the labeling index 
(LI) of the upper 40% of the coionic crypts (95). In an uncontrolled Uia! (n-10), the 
labeling index dropped 33% in sporadic adenoma patients given 200 pg of selenium for 1 
month (16). In a one month randomized placebo-controlled four-armed parallel group trial 
in sporadic colorectal adenoma patients (n=48), those given 750 mg vitamin C had a 54% 
drop in LI, those given 9 mg [3-carotene had a 41% drop, and those given 160 mg a- 
tocopherol or placebo had no change (15). Finally, in a trial in familial polyposis patients 
(n=17), those given 3.0 g ascorbic acid daily had a 19% greater reduction in the labeling 
index than those on placebo (14).
Antioxidant micronutrients have reduced polyp formation in small trials in humans, but not 
in all larger full-scale trials. In the most striking randomized, placebo-controlled clinical trial 
of polyp recurrence, sporadic colorectal adenoma patients (n=209) treated with 30,000 IU 
vitamin A, 70 mg vitamin E plus 1.0 g vitamin C daily over 18 months had a polyp 
recurrence rate of 5.7% vs 35.9% for those on placebo (pO.001) (107). In a pilot 
randomized, placebo-controlled trial, sporadic colorectal adenoma patients (n=129) treated 
with 400 mg vitamin E plus 400 mg ascorbic acid daily over 2 years had a polyp recurrence 
rate of 41.4% vs 50.7% for those on placebo (not statistically significant) (65). In three 
small trials of polyp recurrence in familiar polyposis patients, two testing 3.0 g ascorbic acid 
daily (19,95) and the other testing 4.0 g ascorbic acid plus 400 mg a-tocopherol daily (24) 
small reductions in polyp formations were suggested. However more recently the lack of 
efficacy of administering 400 mg vitamin E , 25 mg (3-carotene, and 1000 mg vitamin C 
have been reported in reducing adenoma recurrence over a 4-yr period (34). This was an 
excellent study (n=751) that did exactly what it was designed to do: determine the efficacy 
of the above treatment regimen on colorectal polyp recurrence in established polyp formers 
over a relatively brief period of time. Based on what was known at the time the study was
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the question is still rather wide open. One reason that this study (34) may not have yielded
hypothesized results is that when originally designed it did not take into account the findings 
(131) that multiple slowly accumulated genetic alterations are usually required to produce ?. 
colonic neoplasm in the non-FAP (Familial Adenomatous Polyposis) patient. It would be 
unrealistic to think that every potential protective factor can protect against cancer by 
inhibiting every step in this pathway and antioxidants are no exception. If a patient already 
has several cell lines with the requisite accumulated genetic changes to commit the cell lines 
to adenoma formation, there may be no mechanism whereby antioxidants could block the 
growth of the commited lines. We know that patients with incident adenoma are likely to 
form recurrent adenoma: thus, it is likely that by the time a patient has an incident adenoma, 
other cell lines are genetically altered to form adenomas also. We also know that the natural 
history of adenoma growth is rather slow. This all means , if a protective agent exerts it’s 
action prior to full genetic commitment of a cell to adenoma formation, a reduction in polyp 
recurrence may not be seen until a substantial proportion of the already commited cell lines 
have „played out”, and it may take longer than the 4 yr follow up of the above mentioned 
study. So antioxidants may not be excluded as protective agents against colon cancer based 
on similar theoretical grounds.
Colon carcinogenesis can be thought of as a long term, multistep process, in which 
multiple somatic genetic defects are accumulated. The possibility exist that various factors 
can can influence the occurence or even the reversal of each of the steps (Fig. 36.) By 
inference, the posibility exists that, even after several steps have occured the entire process 
can be reversed. The likelihood of reversing the entire process is greater when few rather 
than many steps have occured. A given environmental (dietary7) factor (e.g. vitamin A) may
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play a role at one or more than one steps Regarding to the above cited studies and and our 
result carotenoids and other antioxidants may inhibit the first 3-4 steps. Furthermore a
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Fig. 36. A model of diet and nutrition in the etiology and prevention of colorectal cancer
l.Diet factors increasing risk
The outcome ot some prospective studies (including tne particularly conclusive tsasie study;
support the potential chemopreventive role of carotenoids. It has been demonstated that lower 
levels of retinol and carotene et entry were associated with a significantly increased relative risk 
for bronchus cancer, colorectal cancer and all other cancers. At base-line ot the study, ail 
principal antioxidant micronutritients of 2974 clinically healthy males were assayed prior to 
measurable antioxidant decay in frozen plasma (118,119). The 12-year follow-up study detected 
that the mortality from all cancers increased overmultiplicatively at simultaneous occurence of 
low levels of retinol and carotene. This was reconfirmed by the 17-year evaluation with regard to 
overall cancer mortality and further specified for an overmultiplicative increase of mortality from 
bronchus cancer at low lewels of the checked compounds.
Few studies indicated a positive correlation between carotene intake and carcinogenesis. 
The B-Carotene and Retinol Efficacy Trial (CARET) (38,94) randomized 18 314 men and 
women at high risk for lung cancer because of cigarette smoking history or occupational 
asbestos exposure to daily treatment with a combined supplement containing B-carotene (30 
mg) and vitamin A (25 000 IU) or placebo. The trial was terminated early, after 
approximately 4 year of treatment based primarily on interim data analyses suggesting it was 
unlikely any material benefits would emerge with continuation to its scheduled termitation, 
but also besause of emerging data compatible with another findings (The Alpha-Tocopherol, 
B-Carotene Cancer Prevention Study) (39,40). Specifically, there was a nonsignificant 26% 
increase in cardiovascular disease mortality among those assigned the supplementation 
combination. There was a statistically significant 28% increased risk of lung cancer in the 
treated group and a significant 17% increase in the total mortality (38,94). Independent 
effects of the study interventions could not be-established because the study agent were 
given combined.
The Physicians Health Study (PUS) (115) randomised 22 071 US male physicians io 
alternate daily 50 mg fi-carotene and 325 mg Aspirin, both active treatment, or both 
placebo. There was no significant effect of B-carotene on total cancer incidence.
Several problems have been pointed out with these three studies. If the effect of 13- 
carotene (or other antioxidants) is to protect against the initiation of carcinogenesis, all 
three trials were much too short in duration. However B-carotene is only one among the 
hundreds of identified carotenoids, only B-carotene and vitamin A were tested in these 
studies. It is likely that a balanced mixture of carotenoids and other vitamins (as found in 
vegetables and fruits) is able to prevent carcinogenesis. Moreover, there is a possibility that 
a large intake of B-carotene might inhibit the absorption of other protective substances. The 
evidence on this is still conflicting. Two studies have shown that supplementary B-carotene 
was associated with a decrease in serum lutein and zeaxanthin (41).
Missing correlations between retinol intake and cancer risk may not be generalized 
(136,140). First, the benefits of an increased vitamin A intake may only be expected if a 
prevalent suboptimal supply is corrected, as actually true for any essential nutrient (41). 
Second, cancer risk is unlikely to be reduced by any single "magic bullet" nutrient (10).
Despite a large number of studies demonstrating protection by carotenoids, the exact 
mechanisms through which these compounds influence carcinogenesis have not yet been 
proved, but numerous mechanisms of action have been hypothesised. Their beneficial 
effects originate partially from the vitamin A activity, on the other hand they are 
connected with the structure of carotenoids. Retinol dependent pathways: Retinoids 
exert most of their effects by modulating gene expression (35). These effects depend on 
retinoid acid and retinoid X receptors, which act as transcription factors (62). Retinoids 
regulate the growth, morphogenesis and differentiation of cells. They have a variety of
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effects on the cell membrane (128) and they can influence different enzymes (27,126). 
These compounds exert also immunomodulatory effects (62).
Depends on the stucture: Carotenoids are non-enzymatic antioxidants (36), therefore 
they are able to prevent genetic changes by preventing DNA damage caused by free 
radicals (122). They modulate membrane functions and stabilise initiated cells in 
promotional phase of carcinogenesis.
Our study provides new data supporting the importance of nutrients in the polyp cancer 
sequence in colorectal cancer. These results indicate that the deficiency of carotenoids may 
be one of the factors in the development of colorectal cancer arising from adenomas and 
other GI cancers, furthermore not only vitamin A activity is responsible for this supposed 
preventive effect in carcinogenesis.
6. NEW RESULTS
1. Vitamin A and P-carotene decreased dose-sependentiy the number and severity of 
gastric mucosal lesions.
2. The gastric cytoprotective effect of retinoids produces a dose dependent inhibition on 
the extent of ATP transformation to ADP, meanwhile it produces an increase in the 
transformation of ATP into cAMP, indicating their intracellular metabolic effects.
3. The significant decrease of five serum carotenoids have been proved in CD patients 
(vitamin A, zeaxanthin, lutein, a-, P-carotene), furthermore a strong correlation 
between vitamin A level and CDAI.
4. Our investigations have shown the deficiency of certain serum carotenoids in other 
inflammatory (ulcerative colitis - vitamin A and P-carotene) and premalignant GI 
diseases (colorectal polyps-vitamin A and zeaxanthin).
5. Vitamin A and zeaxanthin were depleted in the serum of patients with different GI 
malignant diseases (esophagus, gastric, pancreas, hepatocellular, colorectal carcinoma) 
except of zeaxanthin in patients with pancreas adenocarcinoma.
6. The serum levels of vitamin A precursors decreased only in patients with IBD-s 
significantly.
7. Furthermore vitamin A deficiency has been proved in patients with HCV hepatitis (the 
similar result of patients with alcoholic cirrhosis is well known as a consequence of 
exhausted liver reserves).
Further studies, including the composition of vitamins in the diet and investigation of 
vitamin absorption are necessary to clarify the vitamin status in IBDs. These approaches
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seem to reveal more information to the necessity of intensive nutritional care concerning
Our data support the importance of micronutrients in colorectal polyp-cancer sequence. We 
plan to measure the tissue levels of carotenoids in premalignant and malignant G1 diseases.
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